Sermorelin · 5MG

Sermorelin (also known as GHRH 1-29 or GRF 1-29) is a synthetic 29-amino-acid peptide corresponding to the N-terminal active fragment of human growth hormone–releasing hormone (GHRH). Originally developed by Lance Frohman's group and characterized in the 1980s, sermorelin represents the minimum sequence required for full biological activity at the GHRH receptor — the C-terminal portion of native 44-amino-acid GHRH is dispensable for receptor agonism. Sermorelin functions as a selective GHRH receptor agonist that stimulates pulsatile endogenous growth hormone release from anterior pituitary somatotropes, with downstream hepatic IGF-1 production. The compound was historically FDA-approved as Geref® (Serono) in 1997 for pediatric GH deficiency before being discontinued commercially. Sermorelin has been investigated extensively in preclinical research for GHRH receptor pharmacology, somatotropic axis signaling, and age-related GH decline research models.

Benefits (Research Focus)

• GHRH receptor agonism — studied as the prototypical natural GHRH analog for receptor pharmacology research

• Pulsatile GH release — investigated for physiologic-pattern growth hormone release from pituitary somatotropes

• IGF-1 axis signaling — explored for downstream hepatic IGF-1 production and somatotropic endpoints

• Age-related GH decline research — examined in aged rodent models of somatotropic axis function

• Combination pharmacology — researched alongside GHS-R agonists (e.g., ipamorelin, MK-677) for paired pathway studies

What Researchers Look At

• Plasma GH and IGF-1 dynamics following sermorelin administration

• GHRH receptor binding affinity and pituitary somatotrope responses

• Comparative pharmacology versus modified GHRH analogs (CJC-1295 No DAC, tesamorelin)

• DPP-IV cleavage kinetics and short half-life pharmacokinetics

• Age-associated changes in pituitary GH responsiveness in research models

Quick Specs

• Form: Lyophilized white powder

• Net Peptide Content: 5 mg per vial

• Quantity: 1 vial

• Appearance: White to off-white lyophilizate

• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)

• Purity: ≥99% by HPLC

• Identity: MS-verified (per COA)

• Storage: Protect from light

Identity Basics

• Compound: Sermorelin

• Synonyms: GRF 1-29; GHRH 1-29; GRF(1-29)NH₂; Geref (discontinued FDA-approved brand name)

• Class: Natural unmodified GHRH(1-29) analog; selective GHRH receptor agonist; 29 amino acids

• Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂

• Formula / M.W.: C₁₄₉H₂₄₆N₄₆O₄₂S, ~3357.88 g/mol

• CAS: 86168-78-7

⚠️ Disclaimer

• This product is intended for laboratory research use only.
• Not for human or veterinary use.
• Not approved for diagnostic, therapeutic, or medical applications.
• Handle using appropriate laboratory safety procedures and personal protective equipment.

COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.

Janoshik COA — Third-Party Testing

• Sermorelin Batch COA — October 8, 2025